Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
54
SBMFF Quote, Financials, Valuation and Earnings
Last price:
$0.84
Seasonality move
:
-3.14%
Day range:
$0.84 - $0.84
52-week range:
$0.42 - $1.24
Dividend yield:
1.37%
P/E ratio:
30.49x
P/S ratio:
3.57x
P/B ratio:
3.95x
Volume:
--
Avg. volume:
224
1-year change:
98.09%
Market cap:
$15B
Revenue:
$4B
EPS (TTM):
$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SBMFF
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $21.11 |
|
LJUIF
SSY Group Ltd.
|
-- | -- | -- | -- | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SBMFF
Sino Biopharmaceutical Ltd.
|
$0.84 | -- | $15B | 30.49x | $0.01 | 1.37% | 3.57x |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
$0.07 | -- | $672.8M | -- | $0.00 | 0% | 0.95x |
|
HCM
HUTCHMED (China) Ltd.
|
$15.29 | $21.11 | $2.6B | 4.92x | $0.00 | 0% | 4.42x |
|
LJUIF
SSY Group Ltd.
|
$0.40 | -- | $1.2B | 14.08x | $0.01 | 4.63% | 2.02x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$29.17 | -- | $14.4B | -- | $0.00 | 0% | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SBMFF
Sino Biopharmaceutical Ltd.
|
23.1% | 0.898 | -- | 1.14x |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
-- | 0.000 | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.259 | -- | 4.41x |
|
LJUIF
SSY Group Ltd.
|
33.22% | -0.277 | -- | 2.03x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 20.934 | -- | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SBMFF
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
LJUIF
SSY Group Ltd.
|
-- | -- | 12.86% | 19.05% | -- | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | -- | -- |
Sino Biopharmaceutical Ltd. vs. Competitors
-
Which has Higher Returns SBMFF or CKLSF?
CK Life Sciences International (Holdings), Inc. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat CK Life Sciences International (Holdings), Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B CKLSFCK Life Sciences International (Holdings), Inc.-- -- -- -
What do Analysts Say About SBMFF or CKLSF?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CK Life Sciences International (Holdings), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical Ltd. has higher upside potential than CK Life Sciences International (Holdings), Inc., analysts believe Sino Biopharmaceutical Ltd. is more attractive than CK Life Sciences International (Holdings), Inc..
Company Buy Ratings Hold Ratings Sell Ratings SBMFFSino Biopharmaceutical Ltd.0 0 0 CKLSFCK Life Sciences International (Holdings), Inc.0 0 0 -
Is SBMFF or CKLSF More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.733, which suggesting that the stock is 26.711% less volatile than S&P 500. In comparison CK Life Sciences International (Holdings), Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBMFF or CKLSF?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 1.37%. CK Life Sciences International (Holdings), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 65.96% of its earnings as a dividend. CK Life Sciences International (Holdings), Inc. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBMFF or CKLSF?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than CK Life Sciences International (Holdings), Inc. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than CK Life Sciences International (Holdings), Inc.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 30.49x while CK Life Sciences International (Holdings), Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.57x versus 0.95x for CK Life Sciences International (Holdings), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBMFFSino Biopharmaceutical Ltd.3.57x 30.49x -- -- CKLSFCK Life Sciences International (Holdings), Inc.0.95x -- -- --
-
Which has Higher Returns SBMFF or HCM?
HUTCHMED (China) Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About SBMFF or HCM?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $21.11 which suggests that it could grow by 38.03%. Given that HUTCHMED (China) Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBMFFSino Biopharmaceutical Ltd.0 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is SBMFF or HCM More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.733, which suggesting that the stock is 26.711% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.83%.
-
Which is a Better Dividend Stock SBMFF or HCM?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 1.37%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 65.96% of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBMFF or HCM?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 30.49x while HUTCHMED (China) Ltd.'s PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.57x versus 4.42x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBMFFSino Biopharmaceutical Ltd.3.57x 30.49x -- -- HCMHUTCHMED (China) Ltd.4.42x 4.92x -- --
-
Which has Higher Returns SBMFF or LJUIF?
SSY Group Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat SSY Group Ltd.'s return on equity of 19.05%.
Company Gross Margin Earnings Per Share Invested Capital SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B LJUIFSSY Group Ltd.-- -- $1.4B -
What do Analysts Say About SBMFF or LJUIF?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand SSY Group Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical Ltd. has higher upside potential than SSY Group Ltd., analysts believe Sino Biopharmaceutical Ltd. is more attractive than SSY Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBMFFSino Biopharmaceutical Ltd.0 0 0 LJUIFSSY Group Ltd.0 0 0 -
Is SBMFF or LJUIF More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.733, which suggesting that the stock is 26.711% less volatile than S&P 500. In comparison SSY Group Ltd. has a beta of 0.039, suggesting its less volatile than the S&P 500 by 96.073%.
-
Which is a Better Dividend Stock SBMFF or LJUIF?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 1.37%. SSY Group Ltd. offers a yield of 4.63% to investors and pays a quarterly dividend of $0.01 per share. Sino Biopharmaceutical Ltd. pays 65.96% of its earnings as a dividend. SSY Group Ltd. pays out 48.86% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBMFF or LJUIF?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than SSY Group Ltd. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than SSY Group Ltd.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 30.49x while SSY Group Ltd.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.57x versus 2.02x for SSY Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBMFFSino Biopharmaceutical Ltd.3.57x 30.49x -- -- LJUIFSSY Group Ltd.2.02x 14.08x -- --
-
Which has Higher Returns SBMFF or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About SBMFF or RGC?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Sino Biopharmaceutical Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBMFFSino Biopharmaceutical Ltd.0 0 0 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is SBMFF or RGC More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.733, which suggesting that the stock is 26.711% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBMFF or RGC?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 1.37%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 65.96% of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBMFF or RGC?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 30.49x while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.57x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBMFFSino Biopharmaceutical Ltd.3.57x 30.49x -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
-
Which has Higher Returns SBMFF or UNBSF?
Uni-Bio Science Group has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat Uni-Bio Science Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B UNBSFUni-Bio Science Group-- -- -- -
What do Analysts Say About SBMFF or UNBSF?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Uni-Bio Science Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical Ltd. has higher upside potential than Uni-Bio Science Group, analysts believe Sino Biopharmaceutical Ltd. is more attractive than Uni-Bio Science Group.
Company Buy Ratings Hold Ratings Sell Ratings SBMFFSino Biopharmaceutical Ltd.0 0 0 UNBSFUni-Bio Science Group0 0 0 -
Is SBMFF or UNBSF More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.733, which suggesting that the stock is 26.711% less volatile than S&P 500. In comparison Uni-Bio Science Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBMFF or UNBSF?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 1.37%. Uni-Bio Science Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 65.96% of its earnings as a dividend. Uni-Bio Science Group pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBMFF or UNBSF?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than Uni-Bio Science Group quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than Uni-Bio Science Group's net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 30.49x while Uni-Bio Science Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.57x versus -- for Uni-Bio Science Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBMFFSino Biopharmaceutical Ltd.3.57x 30.49x -- -- UNBSFUni-Bio Science Group-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
